Cognition Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC to sell up to $35 million of common stock over 36 months. Preliminary unaudited operating results for 2022 show a net loss of $21.4 million and $41.6 million in cash and cash equivalents.